Cullinan Therapeutics, Inc. (CGEM)
$21.70-$0.90 (-3.98%) Today
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
https://www.cullinantherapeutics.comSEC filings for CGEM on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 38,000 | $750K |
| Grant or award | 8 | 148,849 | |
| Option exercise | 4 | 68,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
49 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jennifer Michaelson - Officer | Option exercise | Common Stock | 30,000 | $4.30 | $129K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 30,000 | $20.26 | $608K | |
| Jennifer Michaelson - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Jennifer Michaelson - Officer | Option exercise | Common Stock | 4,000 | $4.30 | $17K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 8,000 | $17.82 | $143K | |
| Jennifer Michaelson - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| Jacquelyn L. Sumer - Officer | Grant or award | Common Stock | 2,470 | $8.60 | $21K | |
 Mary Kay Fenton - Officer | Grant or award | Common Stock | 1,541 | $8.60 | $13K | |
| Anthony Rosenberg | Grant or award | Stock Option (Right to Buy) | 25,319 | $0.00 | - | |
| David D. Meek | Grant or award | Stock Option (Right to Buy) | 25,319 | $0.00 | - | |
| Stephen W. Webster | Grant or award | Stock Option (Right to Buy) | 25,319 | $0.00 | - | |
| Andrew R. Allen | Grant or award | Stock Option (Right to Buy) | 21,781 | $0.00 | - | |
 Mary Thistle | Grant or award | Stock Option (Right to Buy) | 25,319 | $0.00 | - | |
| Mittie Doyle | Grant or award | Stock Option (Right to Buy) | 21,781 | $0.00 | - | |
| Jennifer Michaelson - Officer | Option exercise | Common Stock | 4,000 | $4.30 | $17K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 7,800 | $14.60 | $114K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 200 | $15.58 | $3K | |
| Jennifer Michaelson - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| Jennifer Michaelson - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| Jennifer Michaelson - Officer | Option exercise | Common Stock | 4,000 | $4.30 | $17K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 8,000 | $15.68 | $125K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 1,780 | $14.14 | $25K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 1,752 | $13.99 | $25K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 3,601 | $14.47 | $52K | |
| Nadim Ahmed - Officer | Open-market sale | Common Stock | 13,515 | $14.47 | $196K | |
| Jeffrey Alan Jones - Officer | Open-market sale | Common Stock | 4,582 | $14.47 | $66K | |
| Jacquelyn L. Sumer - Officer | Open-market sale | Common Stock | 3,601 | $14.47 | $52K | |
| Jeffrey Alan Jones - Officer | Open-market sale | Common Stock | 4,982 | $13.62 | $68K | |
| Jennifer Michaelson - Officer | Option exercise | Common Stock | 8,000 | $4.30 | $34K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 3,742 | $13.62 | $51K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 8,000 | $14.30 | $114K | |
| Jennifer Michaelson - Officer | Option exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | - | |
| Jacquelyn L. Sumer - Officer | Open-market sale | Common Stock | 3,742 | $13.62 | $51K | |
| Nadim Ahmed - Officer | Open-market sale | Common Stock | 16,381 | $13.62 | $223K | |
| Mary Kay Fenton - Officer | Open-market sale | Common Stock | 4,398 | $13.62 | $60K | |
| Jacquelyn L. Sumer - Officer | Grant or award | Stock Option (Right to Buy) | 230,000 | $0.00 | - | |
| Jeffrey Alan Jones - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Nadim Ahmed - Officer | Grant or award | Stock Option (Right to Buy) | 828,000 | $0.00 | - | |
| Corrine Savill - Officer | Grant or award | Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| Mary Kay Fenton - Officer | Grant or award | Common Stock | 68,750 | $0.00 | - | |
| Mary Kay Fenton - Officer | Grant or award | Stock Option (Right to Buy) | 137,500 | $0.00 | - | |
| Jennifer Michaelson - Officer | Grant or award | Common Stock | 57,500 | $0.00 | - | |
| Jennifer Michaelson - Officer | Grant or award | Stock Option (Right to Buy) | 115,000 | $0.00 | - | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 416 | $12.03 | $5K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 4,000 | $12.30 | $49K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JENNIFER MICHAELSON | Officer | 30,000 | $588K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Cullinan Therapeutics, Inc. (CGEM) had 10 insider filings in the last 90 days, with the most recent on 2026-08-14. The full record for CGEM runs to 49 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CGEM were filed in the last 90 days. 8 purchases are on record for this company.
2 insider sales of CGEM were filed in the last 90 days, totaling $750K.
This page tracks CGEM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CGEM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
